<DOC>
	<DOCNO>NCT00934713</DOCNO>
	<brief_summary>The study design evaluate efficacy montelukast symptom-free day unselected group young child wheeze recurrent asthma like symptom . The secondary aim evaluate effect montelukast lung function , airway responsiveness , airway inflammation use rescue medication .</brief_summary>
	<brief_title>The Effect Montelukast Treatment Wheezy Infants</brief_title>
	<detailed_description>The aim study investigate effectiveness montelukast wheezy young child persistent respiratory symptom . This study prospective , double-blind , placebo-controlled study 6 24 month old child , least one physician-diagnosed wheeze episode persistent asthmatic symptom . Patients randomise placebo montelukast 4 mg / day 8 week period . The clinical response treatment determine , functional residual capacity ( FRC ) specific air-way conductance ( sGaw ) measure use infant whole-body pletys-mograph , maximal flow functional residual capacity ( VÂ´maxFRC ) re-corded use squeeze technique airway responsiveness evaluate perform dosimetric methacholine challenge test .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Signs Symptoms , Respiratory</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>least one physiciandiagnosed wheeze episode history recurrent cough , dyspnoea wheeze successfully perform methacholine challenge test include . use ICS within 8 week prior first visit , cumulative lifetime systemic prednisolone use 3 day dose 2 mg/kg , equipotent dose another systemic corticosteroid ICS use 4 week , respiratory infection 14 day precede lung function measurement obvious tracheobronchomalacia structural defect .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>montelukast , young child , lung function test</keyword>
</DOC>